By Sabrina Serani, Matthew Oser, MD – Targeted Oncology –
While there have been notable breakthroughs for the treatment of small cell lung cancer (SCLC) in recent years, there is still a relative dearth of targeted therapies for this aggressive subtype. Researchers have sought to address this need by developing cell-permeable, orally bioavailable macrocyclic peptides.
In an interview with Targeted Oncology, Matthew Oser, MD, associate professor of medicine at Dana-Farber Cancer Institute and Harvard Medical School, discusses this research and its implications for future research and development in this field.
